ST2/MyD88 deficiency protects mice against aGVHD and spares T-regulatory cells by Griesenauer, Brad et al.
ST2/MyD88 deficiency protects mice against aGVHD and spares 
T-regulatory cells
Brad Griesenauer#1, Hua Jiang#1, Jinfeng Yang#1, Jilu Zhang1, Abdulraouf M Ramadan1, 
Jane Egbosiuba1, Khaled Campa1, and Sophie Paczesny1
1Indiana University School of Medicine, Indianapolis, IN, USA
#
 These authors contributed equally to this work.
Abstract
Acute graft-versus-host disease (aGVHD) hinders the efficacy of allogeneic hematopoietic cell 
transplantation (HCT). Plasma levels of soluble ST2 (sST2) are elevated in human and murine 
aGVHD and correlated to type 1 T cells response. Membrane-bound ST2 (ST2) signals through 
the adapter protein MyD88. The role of MyD88 in T cells during aGVHD has yet to be elucidated. 
We found that knocking out MyD88 in the donor T cells protected against aGVHD independent of 
IL-1R and TLR4 signaling in two murine HCT models. This protection was entirely driven by 
MyD88−/− CD4 T cells. Transplanting donor MyD88−/− conventional T cells (Tcons) with WT or 
MyD88−/− regulatory T cells (Tregs) lowered aGVHD severity and mortality. Transcriptome 
analysis of sorted MyD88−/− CD4 T cells from the intestine ten days post-HCT showed lower 
levels of Il1rl1 (gene of ST2), Ifng, Csf2, Stat5, Batf, and Jak2. Transplanting donor ST2−/− Tcons 
with WT or ST2−/− Tregs showed a similar phenotype with what we observed when using donor 
MyD88−/− Tcons. Decreased ST2 was confirmed at the protein level with less secretion of sST2 
and more expression of ST2 compared to WT T cells. Our data suggests that Treg suppression 
from lack of MyD88 signaling in donor Tcons during alloreactivity uses the ST2 but not the IL-1R 
or TLR4 pathways, and ST2 represents a potential aGVHD therapeutic target sparing Tregs.
INTRODUCTION
Allogeneic HCT (HCT) is a validated curative therapy for patients with hematological 
malignancies and nonmalignant diseases. However, acute graft-versus-host disease 
(aGVHD) is a leading complication of HCT, restricting its effectiveness. Gastrointestinal 
damage from alloreactive T cells is the most correlated to aGVHD-related mortality (1, 2). 
Damage caused during aGVHD to the gastrointestinal tract leads to release of alarmins and 
products of commensal bacteria as well as production of pro-inflammatory cytokines (3, 4). 
To help mediate this response, many cells release decoy receptors that do not signal, one of 
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which is soluble ST2 (sST2) (5). Plasma levels of sST2 are elevated in human (6–13) and 
murine (14, 15) aGVHD and parallel type 1 T cell responses, which drive aGVHD (16).
During conditioning for HCT, systemic IL-33 levels are increased due to its release 
primarily by non-hematopoietic cells (17). This is followed by an increase of sST2 post-
HCT, mediated primarily by the donor T cells (14). We recently reported that ST2 blockade 
using a neutralizing anti-ST2 antibody can attenuate aGVHD by decreasing sST2 secreted 
by T cells while maintaining membrane-bound ST2 (ST2) signaling in T cells (14). Both 
sST2 and ST2 bind IL-33, with sST2 sequestering free IL-33, preventing signaling, and 
IL-33/ST2 signaling through the adapter protein myeloid differentiation primary response 
gene 88 (MyD88) (18). ST2 pathway activation helps drive type 2 responses (19) and 
enhance Treg immunosuppressive function (20–22), which both prevent aGVHD (15, 23, 
24). Indeed, ST2 blockade using a neutralizing anti-ST2 antibody during aGVHD increases 
systemic levels of IL-33, leading to more IL-33 availability for regulatory T cells (Tregs) 
(14). This suggests that there is a balance between IL-33, sST2-secreting T cells, and 
membrane-bound ST2 T cells that regulates inflammation during aGVHD.
The IL-1 receptor (IL-1R) superfamily and toll-like receptor (TLR) family, except TLR3, 
also signal through MyD88 (25, 26). MyD88 was first identified in antigen presenting cells 
(APCs) (27, 28). However, in a murine model, MyD88 signaling in host hematopoietic cells 
has been shown to be completely dispensable for aGVHD induction (29). In T cells MyD88 
is also expressed (28), but its function is less well understood. In CD4 T cells stimulated 
with ovalbumin or a peptide to the haplotype H2b, MyD88 deficiency decreases T cell 
proliferation and type 1 cytokine production through loss of IL-1 receptor (IL-1R) signaling, 
which is dependent on Tregs being present (30). In aGVHD loss of IL-1R signaling in donor 
T cells ameliorated disease (31). The role of MyD88 signaling in donor T cells during 
alloreactivity is not known. We hypothesized that loss of MyD88 in the donor T cells would 
alleviate aGVHD through IL-1R, TLR4, sST2, or a combination of these.
METHODS
Mice.
Boy/J (C57BL/6.Ptprca, H-2b, CD45.1) and C57BL/6 (H-2b, CD45.2) mice were purchased 
from the In Vivo Therapeutics Core at the Indiana University School of Medicine. BALB/c 
(H-2d, CD45.2) and C3H.SW (H-2b, CD45.2) were bred at the Indiana University School of 
Medicine. B6.B10ScN-Tlr4lps-del/JthJ (TLR4−/−) mice were purchased from Jackson 
Laboratory (Bar Harbor, ME). MyD88−/− mice provided by Dr. Steve Kunkel and 
(University of Michigan, Ann Arbor, MI), ST2−/− mice provided by Dr. Andrew McKenzie 
(University of Cambridge, Cambridge, UK), and IL-1R−/− mice provided by Dr. Travis Jerde 
(Indiana University Purdue University of Indianapolis, Indianapolis, IN) were backcrossed 
on a C57BL/6 background for at least 10 generations. C57BL/6 ST2−/−MyD88−/− mice were 
generated in house by crossing C57BL/6 ST2−/− and C57BL/6 MyD88−/−. Loss of MyD88 
and ST2 were verified by PCR. The Institutional Animal Care and Use Committee approved 
all animal protocols.
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aGVHD induction and assessment.
Mice underwent HCT as previously described (14). Briefly, in a major MHC-mismatched 
model (B6 → BALB/c), BALB/c recipient mice received 900 cGy of total body irradiation 
(137Cs as source) at day −1. In a miH-mismatched aGVHD model (B6 → C3H.SW), 
C3H.SW recipient mice received 1100 cGy of total body irradiation at day −1. Then, 
recipient mice were injected intravenously with WT B6 T cell–depleted (TCD) BM cells (5 
× 106) plus WT, MyD88−/−, IL-1R−/−, TLR4−/−, ST2−/−, or ST2−/−MyD88−/− splenic total T 
cells, or CD4+, CD8+ T cells (1 × 106 for BALB/c and 2 × 106 for C3H.SW, unless indicated 
otherwise) from either syngeneic or allogeneic donors at day 0. Splenic T cells from donor 
mice were enriched using the murine Pan T Cell Isolation Kit (Miltenyi Biotec, Auburn, 
CA), and TCD BM was prepared with CD90.2 Microbeads (Miltenyi). Purity of T cell 
isolation from spleen was confirmed via flow cytometry to be >97%. Depletion of T cells 
from BM was confirmed via flow cytometry to be <0.1%. For some experiments, donor T 
cells were first labeled with CFSE before injection. In adoptive transfer models, wild-type, 
MyD88−/− and ST2−/− B6 total donor T cells or Tregs were purified using the murine Pan T 
Cell Isolation Kit and murine CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi). The 
mice were housed in sterilized microisolator cages and maintained on acidified water (pH 
<3) for 3 weeks. Survival was monitored daily and clinical GVHD scores were assessed 
weekly (14).
ELISA.
We measured concentrations of murine plasma IFN-γ using DuoSet Kit and sST2 using 
Quantikine Kit (R&D Systems, Minneapolis, MN) according to manufacturer’s protocols.
Isolation and sorting of intestinal CD4 T cells.
We prepared single-cell suspensions of mononuclear cells from small intestines as 
previously described (14). Briefly, small intestines were flushed with cold PBS to remove 
mucus and feces. The intestines were cut into <0.5 cm fragments and digested in 10 mL of 
DMEM containing 4% bovine serum albumin (Sigma-Aldrich, St. Louis, MO), 2 mg/mL 
collagenase type B (Roche, Indianapolis, IN), and 10 μg/mL DNase I (Roche) at 37°C with 
shaking (250rpm) for 90 minutes. The digested mixture was diluted with 30 mL DMEM, 
filtered through a 100 μm strainer, and centrifuged for 10 minutes at 850g. The cells were 
resuspended in 5 mL of 80% Percoll (GE Healthcare, Little Chalfont, United Kingdom) and 
overlaid with 8 mL of 40% Percoll. The cells were spun at 4°C for 20 minutes at 800g 
without braking. The interface, which contains the live mononuclear cells was collected and 
washed twice with PBS. Live CD4+ T cells (Fixed Viability Dye−CD90.2+CD4+; all from 
eBioscience, Waltham, MA) were stained with fluorescent antibodies and sorted on the BD 
FACSAria (BD Pharmingen, San Diego, CA).
Flow cytometry analysis.
All antibodies and reagents for flow cytometry were purchased from eBioscience, unless 
stated otherwise. Single cell suspensions were preincubated with purified anti-mouse CD16/
CD32 mAb for 10 to 20 min at 4°C to prevent nonspecific binding of antibodies. The cells 
were subsequently incubated for 30 min at 4°C with antibodies for surface staining. Fixable 
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viability dye (FVD) was used to distinguish live cells from dead cells. The FoxP3/
Transcription Factor Staining Buffer Set and the Fixation and Permeabilization Kit were 
used for intracellular transcription factor and cytokine staining. For cytokine staining, cells 
were restimulated with phorbol myristate acetate (PMA; 50 ng/ml), ionomycin (1 mg/ml; 
Sigma-Aldrich), and brefeldin A for 4 to 6 hours before any staining. Staining antibodies 
against mouse antigens included: anti-CD45.1, anti-CD45.2, anti-CD90.2, anti-CD4, anti-
CD8, anti-CD62L, anti-CD44, anti-Foxp3, anti-IL-4, anti-IFNγ, anti-IL-17, and anti-GM-
CSF.
Nanostring analysis.
Sorted intestinal CD4 T cells were prepared and analyzed as previously described (14). 
Briefly, sorted intestinal CD4+CD127+CD25− Tcons from either recipients of WT or 
MyD88−/− allogeneic donor T cells were directly lysed in RLT buffer (Qiagen, Hilden, 
Germany) on ice. Cell concentration for each sample was 2 × 103 cells/μL. Preparation of 
samples for analysis was then performed according to the Nanostring Technologies protocol 
for gene expression. Plates were run on the nCounter SPRINT ProfilerAnalysis System and 
the data analysis using nSolver 3.0. The nCounter Mouse Immunology Kit, which includes 
561 immunology-related mouse genes, was used in the study.
Quantitative RT-PCR.
Total RNA from sorted intestinal T cells (Fixed Viability Dye−CD3+, all from eBioscience), 
were isolated using the RNeasy Plus Mini Kit (Qiagen). Complementary DNA (cDNA) was 
prepared with the SuperScript VILO cDNA Synthesis Kit (Invitrogen, Carlsbad, CA). Using 
an ABI Prism7500HT (Applied Biosystems, Foster City, CA), quantitative real-time PCR 
was performed with the SYBR Green PCR mix. Thermocycler conditions included 2-min 
incubation at 50°C, then at 95°C for 10 min; this was followed by a two-step PCR program: 
95°C for 5 s and 60°C for 60 s for 40 cycles. β-Actin was used as an internal control to 
normalize for differences in the amount of total cDNA in each sample. The primer 
sequences were as follows: actin forward, 5′-CTCTGGCTCCTAGCACCATGAAGA-3′; 
actin reverse, 5′- GTAAAACGCAGCTCAGTAACAGTCCG-3′; mST2 forward, 5′-
AAGGCACACCATAAGGCTGA-3′; mST2 reverse, 5′-TCGTAGAGCTTGCCATCGTT-3′; 
sST2 forward, 5′-TCGAAATGAAAGTTCCAGCA-3′; sST2 reverse, 5′-
TGTGTGAGGGACACTCCTTAC-3′.
Western Blot.
Tcons, CD8+ T cells, and Tregs were isolated from WT B6 spleens using CD4 microbeads 
and CD8 microbeads (both from Miltenyi), respectively, following manufacturer’s protocols. 
Purities of CD4 and CD8 T cells after selection were >95%. Sorted cells were lysed in RIPA 
buffer (Pierce Biotechnology, Waltham, MA) with Pierce Phosphatase Inhibitor MiniTablets 
(Pierce Biotechnology) and Protease Inhibitor Cocktail Tablets (Roche). Samples were 
boiled, electrophoretically separated, and transferred on Immobilon-FL polyvinylidene 
difluoride membranes (MilliporeSigma, Burlington, MA). The blots were blocked with 
Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE) for 1 hour at room 
temperature and incubated with specific primary antibodies: rabbit MyD88 mAb (D80F5, 
Cell Signaling Technology, Danvers, MA) ST2 mAb (Dj8, MD bioproduct) and anti–β-actin 
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mAb (LI-COR), both at 4°C overnight. IRDye 800CW goat anti-rabbit (LI-COR) and IRDye 
680RD goat anti-mouse IgG polyclonal antibodies (LI-COR) were used as secondary 
detection antibodies for MyD88, ST2 and β-actin, respectively. Fluorescence from blots was 
then developed with the Odyssey CLx Imaging System (LI-COR) according to the 
manufacturer’s instructions.
Immunosuppression assays.
The suppressive capacities of WT and MyD88−/− Tregs were assessed with a CFSE 
inhibition assay as previously published (83). Briefly, CD25 depleted total T cells (Tcons) 
were isolated from WT or MyD88−/− mice splenocytes. Antigen presenting cells (APC) 
were isolated from WT mice splenocytes. Tcons were labeled with CFSE (Invitrogen) and 
plated together with WT or MyD88−/− Tregs at different ratios in the presence of anti-CD3 
(0.25 μg/ml) and APC. After 4 days, proliferation of Tcons was measured by flow 
cytometry.
Statistical Analysis.
Log-rank test was used for survival analysis. Differences between two groups were 
compared using 2-tailed unpaired t tests or Mann-Whitney U test. Bonferroni correction was 
used when comparing multiple groups. All statistical analyses were performed using 
GraphPad Prism, version 7.02. Data in graphs represent mean ± standard error of the mean 
(SEM). P values less than 0.05 were considered significant.
RESULTS
MyD88−/− T cells reduce aGVHD severity and mortality in multiple murine models
First, we tested whether loss of MyD88 affected normal splenic T cells in naïve mice. We 
found no difference in splenic T cell numbers; CD4/CD8 frequency; or naïve, memory, and 
effector frequencies (Fig. 1A). Ability to polarize toward Th1, Th2, or Th17 cells in vitro 
was also not affected by the absence of MyD88 as shown by IFN-γ, IL-4, or IL-17 
production, respectively (Fig. 1B). To explore the role of MyD88 signaling in the donor T 
cells in vivo following HCT, we used two clinically relevant murine allo-HCT models: a 
MHC-major mismatch model (MH) C57BL/6, H-2b → BALB/c, H-2d and a minor 
histocompatibility antigen mismatch (miH) model C57BL/6, H-2b → C3H.SW, H-2b, as 
shown in the upper panel of Fig.1C and 1D. In both models splenic T cells were isolated and 
bone marrow cells were depleted of T cells. In the MH model, C57BL/6 → BALB/c, mice 
receiving WT T cells quickly developed and succumbed to severe aGVHD (median survival 
time: 14 days). However, mice receiving MyD88−/− T cells had decreased aGVHD scores 
and mortality (median survival time: >30 days) compared to mice receiving WT T cells (Fig. 
1C). Using the miH model, C57BL/6 → C3H.SW, we observed a similar decrease in 
aGVHD mortality (median survival time: WT - 43 days; MyD88−/− - >60 days; Fig. 1D). 
These results show that signaling through MyD88 in the donor T cells is critical in the 
pathogenesis of aGVHD.
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Loss of IL-1R and TLR4 on T cells, both upstream of MyD88, does not alleviate aGVHD
To elucidate the mechanism as to why MyD88−/− donor T cells induce less severe aGVHD, 
we targeted upstream receptors of MyD88. The upstream receptors for MyD88 include the 
IL-1 receptor superfamily and the toll-like receptor (TLR) family, with the exception of 
TLR3 (25, 26). One group has shown that MyD88−/− CD4 T cells produce less IFN-γ and 
proliferate less than WT CD4 T cells after immunization and this was due to defective IL-1R 
signaling (30). Another group found that, in an aGVHD model, recipients of IL-1R−/− T 
cells survived longer than recipients of WT T cells (31). Thus, we next asked whether the 
phenotype observed using MyD88−/− donor T cells is mediated through IL-1R. In our 
models, we found no difference between groups in clinical score or survival from mice 
receiving WT or IL-1R−/− donor T cells in either the MH model (median survival time: WT 
- 14 days; IL-1R−/− - 28 days; Fig. 2A) or the miH model (median survival time: WT - 43 
days; IL-1R−/− - 39 days; Fig. 2B). Another group showed that recipients of TLR4−/− BM 
and T cells together reduced aGVHD severity compared to WT recipients through defective 
donor antigen presenting cells (APC) response, but did not test whether TLR4−/− T cell 
response compared to WT was also affected (32). Thus, we asked whether loss of TLR4 on 
the donor T cells could affect aGVHD severity and mortality. Recipients of TLR4−/− donor 
T cells both models did not reduce aGVHD severity and mortality (MH model median 
survival time: WT - 10 days; TLR4−/− - 9 days; Fig. 2C; miH model median survival time: 
WT - 18 days; TLR4−/− - 33 days; Fig. 2D). These data show that IL-1R and TLR4 signaling 
in donor T cells are not necessary for aGVHD induction.
Transplantation of donor MyD88−/− CD4 T cells, but not CD8 T cells, reduces aGVHD 
severity independent of intrinsic MyD88 signaling
MyD88 signaling in T cells has been characterized in both the CD4 and the CD8 
compartments (28, 30, 33, 34). However, the importance of MyD88 signaling in donor CD4 
T cells, CD8 T cells, and Tregs in the context of aGVHD has not been studied. CD4 T cons, 
CD8 T cells, and Tregs isolated from the spleen of naïve WT mice expressed MyD88, with 
CD4 T cons cells expressing approximately 3 times more MyD88 than CD8 T cells (Fig. 
3A). To determine if MyD88 in CD4 T cells, CD8 T cells, or both is important for aGVHD 
development, we isolated WT CD4, WT CD8, MyD88−/− CD4, and MyD88−/− CD8 T cells 
from naïve mice. Transplanting MyD88−/− CD4 T cells with WT or MyD88−/− CD8 T cells 
increased the survival of the recipient mice compared to transplanting WT CD4 T cells with 
MyD88−/− CD8 T cells (miH model median survival time: MyD88−/− CD8 – 36 days; 
MyD88−/− CD4 - >60 days; Fig. 3B,C), the latter showing a similar phenotype to total WT T 
cell recipients. These data show that MyD88 signaling in CD4 T cells, but not CD8 T cells, 
is needed for optimal aGVHD induction. GM-CSF expression by T cells has been 
implicated in experimental autoimmune encephalomyelitis (EAE), an animal model of 
multiple sclerosis, through a STAT5 dependent mechanism (35, 36). Recently, GM-CSF was 
also implicated in promoting aGVHD through a BATF-dependent mechanism (37). We 
found that production of GM-CSF in the intestine 10 days post-HCT is significantly 
decreased in both transplanted MyD88−/− CD4 T cell groups compared to transplanted WT 
CD4 T cell groups (Fig. 3D).
Griesenauer et al. Page 6
J Immunol. Author manuscript; available in PMC 2020 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The CD4 T cell compartment consists of both pro-inflammatory conventional T cells 
(Tcons) and anti-inflammatory Tregs. MyD88+/+ Tregs prolong allograft survival in both 
organ transplantation and chronic GVHD through a cell-intrinsic mechanism (38). Intrinsic 
MyD88 signaling in CD4 T cells has also been implicated in mounting a proper antiviral 
response (39). We next explored the cell-intrinsic role of MyD88−/− Tregs in aGVHD. After 
singly transplanting Treg-depleted WT or MyD88−/− Tcons and co-transplanting WT Tcons 
with WT or MyD88−/− Tregs, we did not observe differences in either aGVHD severity or 
mortality (MH model median survival time: WT Tcon - 10 days; MyD88−/− Tcon - 10 days; 
WT Tregs - 26 days; MyD88−/− Tregs - 24 days) in both matched groups, which means the 
intrinsic MyD88 signaling in donor T cells does not impact aGVHD (Fig. 3E, F).
MyD88 Tcons require the presence of Tregs for alleviation of aGVHD
Immunization of CD4 specific MyD88−/− mice has been shown to decrease IFN-γ 
production by CD4 T cells compared to WT CD4 T cells; however, IFN-γ levels after 
immunization were the same between WT and MyD88−/− CD4 T cells when Tregs were 
absent (30). As no differences were observed in both single Tcons-transplanted groups, we 
next sought to reveal whether the presence of Tregs is necessary for protection when using 
MyD88−/− donor Tcons in the MH model. Indeed, as shown in Figures 3G and H, use of 
MyD88−/− Tcons with WT or MyD88−/− Tregs, led to aGVHD amelioration. These data 
show that loss of extrinsic MyD88 signaling in Tcons in the presence of Tregs reduces 
aGVHD severity and mortality.
MyD88−/− donor T cells do not have defects in their proliferation, apoptosis, and migration 
markers but show decreased intestinal T cell infiltration, and increased Th2 and Treg 
frequencies following allo-HCT
To determine if the donor MyD88−/− T cells had a defect in proliferation or apoptosis 
markers following allo-HCT, we stained CD45.1 WT T cells and CD45.2 MyD88−/− T cells 
with carboxyfluorescein succinimidyl ester (CFSE) right before transplantation and injected 
a mixture of these cells at a 1:1 ratio into lethally irradiated BALB/c WT recipients. At day 3 
post-HCT, we did not observe a difference in proliferation between groups from donor cells 
collected in the small intestine (Fig. 4A). We then isolated small intestinal lymphocytes at 
day 5 post HCT to test for differences in apoptosis, measured using annexin V. We found no 
differences between groups in apoptosis of T cells in the small intestine at day 5 post-HCT 
(Fig. 4B). Next, we isolated T cells from WT or MyD88−/− mice and transplanted them 
respectively into lethally irradiated BALB/c recipients, together with TCD WT bone marrow 
cells. We compared the expression of migration markers CCR5 and α4β7 as well as the 
quantity of infiltrated lymphocytes that distributed in the intestinal lamina propria at day 10 
post-HCT. We found that although the frequencies of both CCR5+ T cells and α4β7+ T cells 
were not different between WT and MyD88−/− T cells-transplanted groups, the absolute 
numbers of both CCR5+ T cells and α4β7+ T cells were significantly decreased in the 
MyD88−/− T cells-transplanted group than in the WT T cells-transplanted group in our MH 
model (Fig. 4C, D, E). Interestingly, compared to the WT T cells-transplanted group, both 
IL-4 and IL-10-produced intestinal CD4+ T cells were significantly increased in MyD88−/− 
T cells-transplanted group. What’s more, the frequencies of intestinal Tregs and IL-10-
produced Tregs were also, as expected, significantly increased in MyD88−/− T cells-
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transplanted group at day 10 post-HCT (Fig. 4F, G). Taken together, the above data suggest 
that decreased infiltrated T cells and increased inhibitory cytokines expression in CD4 T 
cells and increased Tregs may collaboratively contribute to the improved aGVHD in 
MyD88−/− T cells-transplanted group, rather than due to differences in T cells expansion or 
apoptosis.
ST2/MyD88 signaling in Tcons is necessary for aGVHD development
Transcriptome analysis from day 10 post-HCT in the MH model comparing WT or 
MyD88−/− sorted CD4+CD127+CD25− Tcons recovered from the intestines showed that 
MyD88−/− CD4 Tcons express lower levels of genes involved in the inflammatory response, 
including Il1rl1 (gene of ST2), Ifng, Batf, Csf2 (gene of GM-CSF), Stat5, and Jak2 (Fig. 
5A). MyD88−/− T cells recovered from the intestine at day 10 post-HCT expressed less sST2 
and more ST2 compared to WT T cells (Fig. 5B and C). Systemic levels of sST2 and IFN-γ 
in recipients of MyD88−/− T cells were also decreased at days 5 and 10 post-HCT compared 
to recipients of WT T cells (Fig. 5D and E). These data confirm that alloreactive T cells in 
the intestines produce sST2, as we previously suggested (14). We hypothesized that the 
protective phenotype observed when transplanting MyD88−/− Tcons in the presence of Tregs 
was mediated by a lack of ST2 signaling on donor Tcons. Recipients of ST2−/− Tcons with 
either WT or ST2−/− Tregs had lower aGVHD score and mortality compared to recipients of 
WT Tcons with either WT or ST2−/− Tregs (Fig. 5F and G).
To further show the importance of ST2/MyD88 signaling in donor T cells during aGVHD, 
we generated ST2−/−MyD88−/− double knockout mice (DKO) by crossing ST2−/− and 
MyD88−/− mice. In the MH model, recipients of the donor DKO T cells had lower disease 
severity, resulting in fewer deaths compared to mice receiving WT cells (median survival 
time: WT ~ 9 days; DKO > 30 days (Fig. 6A and B). Although the recipients of DKO T cells 
did exhibit less disease severity compared to recipients of MyD88−/− T cells, survival 
between these groups was not different. Serum levels of sST2 and IFN-γ were also 
significantly lower at day 10 post-HCT in recipients of DKO T cells (Fig. 6C and D). We 
also tested for systemic levels of IL-6 and TNFα but we saw no difference between 
recipients of WT and DKO T cells (data not shown). To determine if DKO Tcons have 
increased susceptibility to Treg-mediated suppression, we performed a suppressive assay. 
We did not see any impairment of Treg suppressive capability when Tregs were either WT or 
DKO or when Tcons were WT or DKO (Fig. 6E).
DISCUSSION
Previous studies using MyD88−/− T cells have shown that MyD88 is necessary for optimal 
CD4 and CD8 T cell responses in vivo (30, 33, 39, 40). We found no differences in the 
ability of T cells to produce IFN-γ, IL-4, or IL-17 under Th1, Th2, or Th17 polarizing 
conditions, respectively, when using αCD3/αCD28 polyclonal stimulation. However, during 
antigen-specific responses, T cells may require MyD88 for optimal differentiation of Th1 
and Th17 cells (28, 30, 33, 39, 40). In the context of aGVHD, we show here that MyD88 in 
T cells is necessary for optimal allo-response. Indeed, loss of MyD88 in the donor T cells 
leads to decreased aGVHD severity and mortality in two different allogeneic murine models: 
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a MH model (C57BL/6, H-2b → BALB/c, H-2d) and a miH model (C57BL/6, H-2b → 
C3H.SW, H-2b). It has been shown that diminished Th1 and Th17 responses due to loss of 
MyD88 are a product of loss of IL-1R signaling on CD4 T cells (30). As well, WT T cells 
upregulate IL-1R on their surface by day 3 post-HCT and transplanting IL-1R−/− donor T 
cells alleviated aGVHD in MH model (C57BL/6 → BALB/c) (31). However, we have 
found that IL-1R−/− donor T cells have no significant loss of effector function, as aGVHD 
was not attenuated in our two models. Our results are more in accordance with what has 
been shown examining MyD88 signaling in T cells in response to viral infection (33, 39, 
40). After transfer of IL-1R−/− or MyD88−/− T cells into RAG−/− mice and infecting with 
vaccinia virus, mice with IL-1R−/− CD8 T cells were able to respond to the infection 
normally while mice with MyD88−/− CD8 T cells mounted a reduced response (40). Similar 
results were found during LCMV infection in CD8 T cells (33). Looking at WT, MyD88−/−, 
and IL-1R−/− CD4 T cells in absence of CD8 T cells in response to LCMV infection, WT 
and IL-1R−/− mice developed wasting disease and had lower virus levels while MyD88−/− 
mice did not develop wasting disease and had higher virus levels due to failure to induce 
LCMV-specific CD4 T cell response. This response was not due to impaired APC function 
(39). Our results also are in accordance with a clinical trial that observed no difference in 
aGVHD outcomes in HCT patients when using prophylactic treatment with IL-1 receptor 
antagonist, an IL-1R inhibitor (41). This discrepancy in our results along with the results in 
the literature looking at anti-viral response and a clinical trial with those shown others could 
be due to the difference in models. One used an immunization model, while our models and 
others use alloresponses and viral responses for stimulation, respectively. It is possible that 
the different use of antigens could impact which receptors become upregulated on T cells. 
IL-1R is upregulated on 2W:I-Ab tetramer-positive T cells but not 2W:I-Ab tetramer-
negative T cells after antigen stimulation. The immunization model also does not take into 
account the presence of a variety of other molecules that would be present in a diseased 
state. PAMPs, DAMPs, and alarmins released during viral infection or during conditioning 
for allo-transplant but not during immunization could impact T cell response to IL-1 
signaling. A difference in the microbiota of the recipient mice could also explain this 
difference. Recent work has shown that the makeup of the intestinal microbiome can affect 
aGVHD severity (42–46). The mice from commercial vendors which are purchased for 
experiments can have significantly different microbiotas which can impact immune response 
(47). Aberrant IL-1/IL-1R signaling has been shown to alter the microbiota in mice (48). We 
purchased the BALB/c mice in our experiments from The Jackson Laboratory while the 
other group purchased their BALB/c mice from Charles River, Harlan, or from the local 
stock of the animal facility at Freiburg University Medical Center (31). It is possible that the 
difference in phenotype we saw compared what has been published is in part due to 
differences in intestinal microbiota of the recipients.
During pre-HCT conditioning, the integrity of intestinal mucosa is impaired, and the 
intestinal epithelial tight junctions will become more permeable. A very recent research has 
indicated that the intestinal epithelial barrier loss is a crucial driver of the GVHD 
propagation (49). With the damage of intestinal epithelial barrier, broad range of DAMPs, 
PAMPs and alarmins will be released and sensed by kinds of immune cells, among of which 
LPS, with other bacterial products, is secreted and then recognized by TLR4 expressed 
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immune cells. Activated TLR4 transducts the signaling downstream via MyD88 adaptor. 
TLR4 is found on both human and murine CD4 T cells, but its function is not well 
understood. One study showed that only naïve murine T cells and not activated T cells 
express TLR4 (50). However, TLR4 on human T cells was only detected in activated CD4 T 
cells (51). In a murine model of EAE, TLR4−/− T cells transferred into RAG1−/− followed 
by EAE induction did not produce disease (52). However, in a spontaneous model of colitis, 
IL-10−/−TLR4−/− T cells transferred into RAG1−/− mice accelerated disease progression 
(53). During aGVHD, we found that TLR4 signaling in donor T cells was not necessary. A 
lack of TLR4 expression on activated T cells could explain why we didn’t see any difference 
when using TLR4−/− donor T cells, but we did not test for TLR4 surface expression post-
HCT. Our data contrasts that found by others, who found that using TLR4−/− as donors does 
protect against aGVHD (32). We believe this difference is caused by the use of TLR4−/− BM 
and TLR4−/− T cells together compared to our use of WT BM and TLR4−/− T cells. As 
donor dendritic cells are present in the BM during transplantation and as it is well 
documented that TLR4 stimulation of dendritic cells triggers their maturation and cytokine 
expression, we believe that the protective phenotype observed is caused by TLR4−/− on these 
dendritic cells. A limitation of this work is that we did not go through the full range of 
MyD88-depedent TLRs. It is possible that other MyD88-dependent TLRs on donor T cells 
are important for aGVHD development (54). For example, TLR2 signaling has been shown 
to promote a Th17 response and that loss of TLR2 on CD4 T cells ameliorated EAE (55); 
however, loss of TLR2 on the donor T cells as well as TLR2 blockade using an anti-TLR2 
blocking antibody did not reduce aGVHD severity or mortality (56).
MyD88 signaling has been shown to be important in both macrophages and T cells in 
responses to viruses, as MyD88−/− T cells show impaired anti-viral clearance (33, 39, 40); 
however, its role in different subsets of T cells in vivo during aGVHD is not known. We first 
compared the expression of MyD88 in three major T cell subpopulations. Western blot data 
indicated that CD4+ T cons have the highest expression of MyD88, nearly three times more 
than CD8+ T cells or Tregs. When transplanting WT CD4 T cells with MyD88−/− CD8 T 
cells, we observed no difference in aGVHD severity or mortality. When transplanting 
MyD88−/− CD4 T cells with WT CD8 T cells, we observed a decrease in aGVHD severity 
and an increase in survival. This is in accordance with the findings that MyD88−/− CD4 T 
cells have impaired function during coronavirus encephalomyelitis while MyD88−/− CD8 T 
cells appear normal (57). Transcriptome analysis using Nanostring of CD4+ T cells from the 
intestine 10 days post-HCT also showed that genes responsible for a potent type 1 response 
to be downregulated in mice receiving MyD88−/− T cells. Interestingly, GM-CSF production 
was lower in MyD88−/− CD4 T cells but not in MyD88−/− CD8 T cells. It has recently been 
shown that loss of GM-CSF in the donor T cells attenuates aGVHD and that GM-CSF 
production in the donor T cells is mediated through basic leucine zipper transcription factor, 
ATF-like (BATF) signaling (37). Our Nanostring data suggests that loss of MyD88 impacted 
BATF expression, as BATF expression is much lower in MyD88−/− CD4 T cells than in WT 
CD4 T cells. Exploration of MyD88/BATF/GM-CSF regulation would help to understand 
how MyD88 affect GM-CSF production.
The CD4 T cell compartment consists of both Tcons and Tregs, with type 1 Tcons 
promoting aGVHD and Tregs alleviating aGVHD. We showed here that transplantation of 
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WT or MyD88−/− Tcons without Tregs demonstrated no difference in aGVHD severity or 
mortality. However, in a colitis model in which naïve WT or MyD88−/− CD4+ CD45RB+ T 
cells were transplanted into RAG1−/− recipients, MyD88−/− cells were unable to induce 
severe colitis as compared to WT cells (58). The discrepancy observed could be due to the 
difference in pro-inflammatory cytokines observed between models. This colitis model is 
dependent on IL-17 production from Th17 cells, and MyD88−/− CD4 T cells did indeed 
produce less IL-17. A difference in the Th1 cytokine IFN-γ was not observed (58). Our 
aGVHD model with this dose of donor T cells is mainly dependent on IFN-γ as we did not 
detect any Th17 cells in the intestine in our models, and IFN-γ was significantly lower in the 
plasma of MyD88−/− recipients. It has been shown that Treg-specific MyD88−/− cells have 
no impairment of suppressive capability compared to WT Treg (30). But, it has also been 
shown that MyD88−/− Tregs during skin transplantation and cGVHD are deficient in their 
suppressive capabilities (38). MyD88−/− Tregs also protect less against colitis compared to 
WT Tregs (58); however, we found that transplantation with donor WT Tcons and either WT 
or MyD88−/− Tregs did not alleviate aGVHD. The difference in our data could be due to the 
kinetics of disease. In the skin transplant model, Treg frequencies were similar early after 
transplant and only started to decrease after 21 days post-skin transplant (38). In the colitis 
model, a difference in disease severity using MyD88−/− Tregs compared to WT Tregs was 
not observed until 9 weeks post-transplant into RAG1−/− mice (58). In our aGVHD model, 
we start seeing severe aGVHD as early as 10 days post-HCT. In the immunization model, 
the authors waited only seven days before measuring Tcons proliferation and pro-
inflammatory cytokine production (30). We cannot eliminate the possibility based off our 
data that, in a slower disease progression setting, MyD88−/− Tregs do indeed develop a 
suppressive defect. Therefore, the importance of MyD88 signaling in Tregs may be highly 
disease and time dependent.
It has been shown that naïve CD4 T cells require MyD88 signaling through the IL-1R in 
order to overcome Treg-mediated suppression for induction of a Th1 response (30). While 
our data suggests that IL-1R signaling in T cells is not required for aGVHD induction, left 
open was the possibility that MyD88 signaling in Tcons is required for Treg-mediated 
suppression in aGVHD. Indeed, when transplanting MyD88−/− Tcons with Tregs, we did 
observe a decrease in aGVHD severity and mortality. Interestingly, this phenotype did not 
depend on MyD88 in the Tregs, as transplanting WT or MyD88−/− Tregs with MyD88−/− 
Tcons showed no difference in aGVHD severity or mortality. We believe that this may be 
caused by loss of signaling through soluble factors, such as IL-6 or TNFα, that act directly 
or indirectly through or on MyD88. Deficiency of IL-1β/MyD88 signaling has already been 
mentioned, but IL-6 has also been implicated in Tcons resistance to Treg-mediated 
suppression (59–61). It has been suggested that this is due to blocking of Treg-mediated 
inhibition of IL-2Rα on Tcons (61). We did not check for IL-2Rα expression on Tcons 
during our experiments. Loss of IL-6-produced T cells, but not bone marrow cells or non-
hematopoietic cells, also prevents aGVHD mortality in a murine model, although the 
mechanism behind this remains unexplored (62). Interestingly, similar to our data with 
MyD88−/− donor T cells, it was also found that the absence of IL-6 did not affect the 
expansion of T cells. As IL-6 is known to be upregulated by multiple TLR/MyD88 signaling 
pathways, it is possible that reduced IL-6 in MyD88−/− donor T cells could explain our 
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phenotype. However, we did not check for IL-6 production in T cells in our models. IL-6 
signaling is known to activate STAT3 (63). It is also possible that the absence of MyD88 
signaling reduces phosphorylated STAT3 levels in the Tcons, which has been shown to be 
important in Tcons for their resistance to Treg suppression (64). Although STAT3 is not 
classically thought to be downstream of MyD88, it has recently been shown that activation 
of TLR4 through MyD88, TLR7, or TLR9 directly leads to phosphorylation of STAT3 (65–
67). Indeed, pSTAT3 Y705 is increased significantly in patient CD4 T cells before onset of 
aGVHD (68). IL-7 and IL-15 may also play a role in Tcons-resistance to Tregs during 
aGVHD (69–71). Adoptive transfer of T cells into lymphopenic hosts, as would be after 
irradiation in our aGVHD models, leads to increased availability of IL-7 and IL-15 for the 
transferred T cells. Although a link between IL-7 and MyD88 has yet to be made, it has been 
shown that IL-15 promotes MyD88 expression in T cells (72). How IL-15 causes MyD88 
upregulation and the effect of MyD88 upregulation by IL-15 has yet to be explored. Tcons 
could be using these pathways mentioned involving MyD88 to redundantly prevent their 
Treg-mediated suppression, which would explain why loss of IL-1R or TLR4 alone was 
insufficient.
A common convergence of all these pathways is the phosphatidylinositol-3 kinase 
(PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. This pathway helps control 
many cellular processes, such as proliferation, survival, migration, and metabolism (73). It 
has been suggested that hyper-activation of PI3K leads to Tcons resistance to Treg-mediated 
suppression (74). Indeed, in murine models that have genetic deficiencies in proteins that 
negatively regulate PI3K signaling, Tcons are more resistant to Treg-mediated suppression 
(75, 76). Several cytokine receptors, TNF receptors, TLRs, and T cell costimulatory 
receptors have been shown to activate PI3K signaling (77). While MyD88 has not been 
implicated in all these pathways, we suspect that loss of MyD88 may affect enough 
pathways to prevent hyper-activation of PI3K/ATK/mTOR signaling, thus rendering Tcons 
susceptible to Treg-mediated suppression (Fig. 7). Direct targeting of mTOR using 
rapamycin has been extensively studied in GVHD and is given to patients routinely as a 
prophylaxis, with some studies suggesting efficacy as a treatment option of aGVHD (78). 
Recently, in a murine model of aGVHD, direct pan-PI3K inhibition using a small molecule 
inhibitor prevented severe aGVHD development, in part through controlling T cell activation 
(79). However, how pan-PI3K inhibition works on Tcons and Tregs specifically was not 
studied nor the direct mechanism of how pan-PI3K inhibition of T cells prevented severe 
aGVHD development.
ST2 on T cells has been found primarily on the Th2 and Treg subsets. ST2 is a member of 
the IL-1R superfamily and signals through MyD88 IL-33/ST2 signaling enhances Th2 and 
Treg activity through increased IL-5 and IL-13 production in Th2 cells (19, 80–82) and 
increased Foxp3 expression in Tregs (21). A soluble form of ST2, sST2, sequesters free 
IL-33 and does not signal. Recently, we have shown that T cells, specifically type 1 and type 
17 T cells, can produce sST2 (14). We and others have shown that total ST2−/− T cells 
ameliorate aGVHD (14, 17). We also find here that Tcons have much higher expression of 
ST2 than CD8+ T cells, but an equivalent expression with Tregs. It should be noticed that 
both MyD88 and ST2 are simultaneously highly expressed in CD4+ Tcons rather than the 
Tregs, which may means a parallel function in Tcons. Due to the similarities of expression, 
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we asked whether the phenotype of MyD88−/− Tcons in the presence of WT or MyD88−/− 
Tregs observed above would be paralleled when using ST2−/− Tcons and WT or ST2−/− 
Tregs. Indeed, transplanting ST2−/− Tcons alleviated aGVHD in a similar manner regardless 
of using WT or ST2−/− Tregs, suggesting that ST2/MyD88 signaling is required for Tcons to 
overcome Treg-mediated suppression. We did notice a small but non-statistically significant 
difference in aGVHD severity and mortality when using ST2−/− Tregs with WT or ST2−/− 
Tcons compared to using WT Tregs with WT or ST2−/− Tcons, suggesting that loss of ST2 
on Tregs may impact their suppressive capabilities. This would be in line with the higher 
expression of ST2 as compared to MyD88 on Tregs (Fig 3A) and what has previously been 
shown (20, 21, 83). In our hands, an in vitro suppression assay did not show any differences 
in suppression by Tregs when either Tcons or Tregs lost both ST2 and MyD88 signaling. 
This possible suggests that the presence of the allo-response and/or pro-inflammatory 
environment during aGVHD allows Tcons to resist suppression. We also show that isolated 
MyD88−/− CD4 T cells from the intestine at day 10 post-HCT express less sST2 and more 
ST2 compared to WT CD4 T cells. However, whether MyD88 signaling is directly important 
in sST2 expression by CD4 T cells or whether the decrease in sST2 expression is due to a 
decrease in Th1 response is not clear. Loss of MyD88 signaling leading to lower sST2 
expression would partially explain the protective phenotype against aGVHD we observed 
when we transplanted MyD88−/− donor T cells as compared with transplanting WT donor T 
cells (Fig. 7). There is evidence that STAT3 and ERK signaling, both of which can be 
activated through MyD88, influence ST2 proximal promoter activity (84), which has been 
suggested to promote sST2 production (85). We have not tested for STAT3 or ERK activity 
in our models. As well, the increase in ST2 expression may be a compensatory mechanism 
by the CD4 T cells trying to overcome the loss of MyD88.
We and others have attempted to look for ST2 expression via flow cytometry on Th1 during 
aGVHD settings without success. However, recent reports have shown that ST2 can indeed 
be present on Th1 cells (17, 86, 87). ST2 signaling on Th1 cells helps clear LCMV infection 
through increased IFN-γ production and is dependent on T-bet and STAT4 (86). The effect 
of IL-33 on Th1 differentiation was also seen by using an OVA-immunization murine model 
as well as human in vitro cell cultures (87). The expression of ST2 on the surface only 
occurred during times of inflammation (86). During aGVHD, IL-33 administration during 
peak inflammatory response (days 3–7 post-HCT) enhanced aGVHD severity and mortality 
(17), while IL-33 administration during the peri-transplant period ameliorated aGVHD 
through enhanced ST2+ Treg response (88). This suggests that ST2 may be only transiently 
expressed on Th1 cells, while it is more stably expressed on Th2 cells and Tregs at later time 
points during aGVHD. Although an inflammatory response is clearly occurring during 
aGVHD, perhaps this transient expression is the reason that we were not able to detect ST2 
in our aGVHD model, as we’ve only looked for ST2 expression via flow cytometry after day 
10 post-HTC. Further work needs to be done to assess a potential role of ST2/MyD88 
signaling in promoting a Th1 response early during aGVHD.
A weakness of our mouse model is that the ST2−/− mouse we use has a loss of both the 
membrane and soluble forms of ST2. It is therefore difficult to determine whether sST2 
production by Tcons or if indeed ST2 is present on Th1 cells and loss of ST2 on these cells 
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is more important in the phenotype we observed. Development of distinct sST2−/− and 
membrane ST2−/− mice could really help answer these questions.
We conclude that loss of ST2/MyD88 protects mice from fatal aGVHD through lower sST2 
production by Tcons while also sparing Treg function. The results of our study confirm that 
ST2 represents an aGVHD therapeutic target.
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Key Points
1. MyD88 deficiency in donor Tcons with Tregs protected against alloreactivity 
and aGVHD
2. This protective effect uses ST2 but not the IL-1R or TLR4 pathways
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Figure 1. 
Both morbidity and mortality of aGVHD are significantly reduced using MyD88−/− donor T 
cells in murine models. (A) Cell numbers and frequencies of total CD4 and CD8 T cells 
(Left), naïve (CD62L+CD44−), memory (CD62L+CD44+), and effector (CD62L−CD44+) 
CD4 or CD8 populations (Right) harvested from spleen of WT or MyD88−/− mice (mean ± 
SEM; n=3). (B) CD4 T cells were stimulated with plate-bound αCD3 (2 μg/ml) and soluble 
αCD28 (5 μg/ml) under Th0 (no additional cytokines), Th1 (20 ng/ml IL-12, 2 ng/ml IL-2), 
Th2 (20 ng/ml IL-4), or Th17 (4 ng/mL TGF-β, 20 ng/ml IL-6) conditions for 5 days. 
Graphs show frequency of IFN-γ (Left), IL-4 (Middle), and IL-17 (Right) expressions 
(mean ± SEM; n=3). (C) Lethally irradiated BALB/c mice (900 cGy) were given 5 × 106 T 
cell depleted bone marrow (TCD-BM) cells and 1 × 106 donor T cells from WT or 
MyD88−/− B6 mice for allogeneic transplant or WT BALB/c TCD-BM and donor T cells 
from WT BALB/c mice for syngeneic transplant. (Left) GVHD score and (Middle) survival; 
BALB/c → BALB/c (n=5), B6 WT (n=15), or B6 MyD88−/− total T cells (n=15) groups. 
(Right) Kinetics of plasma levels of sST2 in BALB/c mice collected at days 5 and 10 post-
HCT (mean ± SEM, n=3). (D) Lethally irradiated C3H.SW mice (1100 cGy) were given 5 × 
106 TCD-BM cells and 2 × 106 donor T cells from WT or MyD88−/− B6 mice for allogeneic 
transplant or WT C3H.SW TCD-BM and donor T cells from WT C3H.SW mice for 
syngeneic transplant. (Left) GVHD score and (Middle) survival; C3H.SW → C3H.SW 
(n=5), B6 WT (n=6), or B6 MyD88−/− total T cells (n=6). (Right) Kinetics of plasma levels 
of sST2 in BALB/c mice collected at days 5 and 10 post-HCT (mean ± SEM, n=3). The ns 
means no significant, *p < 0.05, **p < 0.01
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Figure 2. 
MyD88 signaling on donor T cells through IL-1R or TLR4 does not affect aGVHD severity 
or mortality. (A) Lethally irradiated BALB/c mice (900 cGy) were given 5 × 106 TCD-BM 
cells and 1 × 106 donor T cells from WT or IL-1R−/− B6 mice for allogeneic transplant or 
WT BALB/c TCD-BM and donor T cells from WT BALB/c mice for syngeneic transplant. 
(Left) GVHD score and (Right) survival; BALB/c → BALB/c (n=5), B6 WT (n=15), or B6 
IL-1R−/− total T cells (n=8). (B) Lethally irradiated C3H.SW mice (1100 cGy) were given 5 
× 106 TCD-BM cells and 2 × 106 donor T cells from WT or IL-1R−/− B6 mice for allogeneic 
transplant or WT C3H.SW TCD-BM and donor T cells from WT C3H.SW mice for 
syngeneic transplant. (Left) GVHD score and (Right) survival; C3H.SW → C3H.SW (n=5), 
B6 WT (n=6), or B6 IL-1R−/− total T cells (n=6). (C) Lethally irradiated BALB/c mice (900 
cGy) were given 5 × 106 TCD-BM cells and 1 × 106 donor T cells from WT or TLR4−/− B6 
mice for allogeneic transplant. (Left) GVHD score and (Right) survival; B6 WT (n=8) or B6 
TLR4−/− total T cells (n=8). (D) Lethally irradiated C3H.SW mice (1100 cGy) were given 5 
× 106 TCD-BM cells and 2 × 106 donor T cells from WT or TLR4−/− B6 mice for allogeneic 
transplant. (Left) GVHD score and (Right) survival; B6 WT (n=8) or B6 TLR4−/− total T 
cells (n=8). The ns means no significant.
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Figure 3. 
MyD88−/− CD4 Tcons in the presence of Tregs alleviates aGVHD severity and mortality. 
(A) Western blot of MyD88 from freshly isolated Tcons, CD8 T cells and Tregs from a WT 
B6 spleen. Lethally irradiated C3H.SW mice (1100 cGy) were respectively given 5 × 106 
TCD-BM cells and a mixture (WT CD4 + WT CD8 or WT CD4+MyD88−/− CD8 or 
MyD88−/− CD4 + WT CD8 or MyD88−/− CD4 + MyD88−/− CD8) of 2 × 106 donor T cells. 
(B)The GVHD score and (C) survival are real-time monitored; WT CD4 + WT CD8 (n=13), 
WT CD4+MyD88−/− CD8 (n=13), MyD88−/− CD4 + WT CD8 (n=13) and MyD88−/− CD4 
+ MyD88−/− CD8 (n=4) (D) T cells were harvested from the intestine at day 10 post-HCT 
and stained for live GM-CSF produced CD4 T cells. Lethally irradiated BALB/c mice (900 
cGy) were given 5 × 106 TCD-BM cells with 1 × 106 donor Tcons without Tregs from WT 
or MyD88−/− B6 mice for allogeneic transplant or WT BALB/c TCD-BM and 1 × 106 donor 
T cells from WT BALB/c mice for syngeneic transplant; or with a 5:1 mixture of WT Tcon 
+ WT or MyD88−/− Tregs totaling 1 × 106 donor T cells from B6 mice for allogeneic 
transplant. (E) The GVHD score and (F) survival are real-time monitored; BALB/c → 
BALB/c (n=5), B6 WT Tcons (n=7), B6 MyD88−/− Tcons (n=7), B6 WT Tcons and B6 WT 
Tregs (n=7), B6 WT Tcons and B6 MyD88−/− Tregs (n=7). Lethally irradiated BALB/c mice 
(900 cGy) were given 5 × 106 TCD-BM cells and a 10:1 mixture of WT or MyD88−/− Tcons 
+ WT or MyD88−/− Tregs totaling 1 × 106 donor T cells from B6 mice for allogeneic 
transplant. (G) GVHD score and (H) survival; WT or MyD88−/− Tcons + either WT or 
MyD88−/− Tregs (all groups n=6). The ns means no significant, *p < 0.05, **p < 0.01, 
****p < 0.0001.
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Figure 4. 
MyD88−/− donor T cells do not have defects in proliferation or apoptosis, but a significant 
increase of Tregs and the production of IL-4 and IL-10 during aGVHD. (A, B) Lethally 
irradiated BALB/c mice (900 cGy) were given 5 × 106 TCD-BM cells and 1 × 106 mixture 
of CFSE labeled donor T cells from WT CD45.1 or MyD88−/− CD45.2 (1:1) B6 mice. (A) 
Proliferation of CFSE labeled T cells from WT CD45.1 or MyD88−/− CD45.2 donors 
harvested from the intestine at day 3 post-HCT. (B) Annexin V staining of T cells from WT 
CD45.1 or MyD88−/− CD45.2 donors harvested from the intestine at day 5 post-HCT (mean 
± SEM, n=4). (C-G) Lethally irradiated BALB/c mice (900 cGy) were given 5 × 106 TCD-
BM cells and 1 × 106 donor T cells from WT or MyD88−/− B6 mice respectively. (C) 
Quantity of the infiltrated small intestinal lamina propria lymphocytes in both groups (mean 
± SEM, n=5). (D and E) Expressions of CCR5 and α4β7 in CD4 + T cells and absolute 
numbers of CCR5 and α4β7 positive CD4+ T cells were detected in infiltrated small 
intestinal lamina propria lymphocytes (mean ± SEM, n=5). (F) Percentages of IL-4 and 
IL-10-produced CD4+ T cells in the gut were detected at day 10 post-HCT (mean ± SEM, 
n=5). (G) Frequencies of the Tregs and IL-10-produced Tregs in the gut were also detected 
at day 10 post-HCT (mean ± SEM, n=5). The ns means no significant, *p < 0.05, **p < 
0.01, ***p < 0.001.
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Figure 5. 
MyD88−/− Tcons are more susceptible to Treg-mediated suppression through loss of ST2. 
(A) Transcriptome analysis comparing intestinal WT and MyD88−/− CD4 T cells harvested 
10 days post-HCT (n=2 per group). Lethally irradiated BALB/c mice (900 cGy) were given 
5 × 106 TCD-BM cells and 1 × 106 donor T cells from WT or MyD88−/− B6 mice for 
allogeneic transplant. (B and C) Relative expressions of sST2 and mST2 from WT or 
MyD88−/− T cells harvested from the intestine 10 days post-HCT (mean ± SEM, n=4). (D 
and E) Kinetics of plasma levels of sST2 and IFN-γ in BALB/c mice collected at days 5 and 
10 post-HCT (mean ± SEM, n=3). Lethally irradiated C3H.SW mice (1100 cGy) were given 
5 × 106 TCD-BM cells and a 10:1 mixture of WT or ST2−/− Tcon + either WT or ST2−/− 
Tregs totaling 2 × 106 donor T cells from WT or ST2−/− B6 mice for allogeneic transplant. 
(F) GVHD score and (G) survival were real-time monitored; WT or ST2−/− Tcons + either 
WT or ST2−/− Tregs (all groups n=6). The ns means no significant,*p < 0.05, **p < 0.01, 
***p < 0.001.
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Figure 6. 
ST2−/−MyD88−/− DKO T cells reduce aGVHD severity and mortality similarly to MyD88−/− 
T cells. Lethally irradiated BALB/c mice (900 cGy) were given 5 × 106 TCD-BM cells and 
1 × 106 donor T cells from WT, MyD88−/−, or DKO B6 mice for allogeneic transplant. (A) 
GVHD score and (B) survival were real-time monitored (all groups n=8). (C) Kinetics of 
plasma levels of sST2 and IFN-γ (D) in BALB/c mice collected at days 5 and 10 post-HCT 
(mean ± SEM, n=3). (E) Total Tcons (TCRβ+CD25−) and Tregs (TCRβ+CD4+CD25+) from 
the spleen of naïve WT and DKO mice were harvested via FACs sorting. CFSE-labeled WT 
or DKO Tcons were plated with WT or DKO Tregs at a 2:1, 4:1, or 8:1 ratio and stimulated 
with plate-bound αCD3 (2 μg/mL) and αCD28 (5 μg/mL) for 72 hours. Suppression was 
measured by lack of CFSE dilution. The ns means no significant, *p < 0.05, ***p < 0.001. p 
values in A and B are comparing WT and DKO groups.
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Figure 7. 
Schema of possible mechanisms of action of MyD88−/− donor T cells during aGVHD. 
Various receptor signaling pathways have been shown to use MyD88 as an adaptor protein, 
including all TLRs except TLR3, the IL-1 superfamily of receptors, and recently the IL-15 
receptor. We propose a two-pronged approach as to how MyD88 Tcons are able to resist 
Treg-mediated suppression. First, signaling through MyD88 activates the PI3K/AKT 
pathway. Shortly after conditioning for transplant, the damage caused by the conditioning 
leads to release of various DAMPs, PAMPs, and alarmins that can activate TLR and IL-1R 
superfamily signaling. The loss of lymphocytes after conditioning also causes excessive 
IL-15 to be available. IL-6 is produced and released through IL-1R and TLR signaling and 
can bind to the IL-6R on other Tcons. Both IL-6 signaling and MyD88 signaling can activate 
the PI3K/AKT pathway. Through a yet to be defined mechanism, others have proposed that 
hyper-activation of PI3K/AKT signaling promotes resistance of Tcons to suppression by 
Tregs. Second, we show that sST2 production in Tcons is reduced in MyD88−/− Tcons; 
however, how MyD88 regulates sST2 production is still unknown. sST2 released by Tcons 
can bind free IL-33, preventing IL-33/ST2 signaling on Tregs and Th2. IL-33/ST2 signaling 
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on Tregs and Th2 has been shown by numerous groups to promote Treg function. Blocking 
sST2 with a neutralizing antibody has been shown to increase Treg frequency and ameliorate 
experimental aGVHD. We hypothesize that MyD88−/− Tcons have less PI3K/AKT 
activation and secrete less sST2, allowing the Tcons to be better repressed by Treg cells. 
Solid lines: direct effect; Dashed lines: indirect effect; dotted lines: proposed effect.
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